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Abstract
The BCR–ABL1 fusion gene is the driver mutation of Philadelphia chromosome-positive chronic myeloid leukemia (CML). 
Its expression level in CML patients is monitored by a real-time quantitative polymerase chain reaction defined by the Inter-
national Scale  (qPCRIS). BCR–ABL1 has also been found in asymptomatic normal individuals using a non-qPCRIS method. 
In the present study, we examined the prevalence of BCR–ABL1 in a normal population in southern Sarawak by performing 
 qPCRIS for BCR–ABL1 with ABL1 as an internal control on total white blood cells, using an unbiased sampling method. 
While 146 of 190 (76.8%) or 102 of 190 (53.7%) samples showed sufficient amplification of the ABL1 gene at > 20,000 
or > 100,000 copy numbers, respectively, in  qPCRIS, one of the 190 samples showed amplification of BCR–ABL1 with posi-
tive  qPCRIS of 0.0023% and 0.0032% in two independent experiments, the sequence of which was the BCR–ABL1 e13a2 
transcript. Thus, we herein demonstrated that the BCR–ABL1 fusion gene is expected to be present in approximately 0.5–1% 
of normal individuals in southern Sarawak.
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Introduction
Chronic myeloid leukemia (CML) is a clonal hematological 
malignancy originating from hematopoietic stem cells har-
boring the Philadelphia chromosome (Ph) due to transloca-
tion (9;22). Ph generating the BCR–ABL1 fusion gene was 
the first identified chromosomal anomaly associated with a 
specific malignant disease in humans [1–3]. BCR–ABL1 
tyrosine kinase inhibitors (TKI) are the most successful 
targeted therapy for preventing the progression of CML in 
patients [4, 5]. To evaluate the sensitivity of CML cells to 
TKI, it is important for patients being treated to be quanti-
fied based on the residual amount of the BCR–ABL1 gene in 
blood cells using a real-time quantitative polymerase chain 
reaction (qPCR) with standardization on the International 
Scale (IS) of BCR–ABL1 (BCR–ABL1–qPCRIS) [6, 7].
CML is clinically classified into different disease stages 
such as the chronic phase (CP), acceleration phase (AP), and 
blast crisis (BC), according to phenotypic and laboratory 
data [8]. Pre-clinical CML (pre-CP) was recently proposed 
to be segregated from CP because pre-CP patients do not 
exhibit the clinical features of CP or leukocytosis [9]. While 
pre-CP patients have mildly increased basophil counts and 
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